CA2779052A1 — Pharmaceutical composition of entecavir and process of manufacturing
Assigned to Pharmascience Inc · Expires 2013-11-30 · 12y expired
What this patent protects
The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infection, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutica…
USPTO Abstract
The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infection, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.
Drugs covered by this patent
- Emtriva (EMTRICITABINE) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.